Pulmonary micrometastases of colorectal cancer are detectable far earlier with combination imaging, opening door to improved cancer treatment.
SPECT/CT used with fluorescence could help surgeons tell the difference between tumor tissue and normal tissue, according to a new study from The Netherlands. In a study, published in The Journal of Nuclear Medicine, researchers analyzed data on colorectal cancer that had metastasized beyond the primary tumor. Using a mouse model, investigators identified pulmonary micromestastases of colorectal cancer with labetuzumab, an antibody that targets carcinoembryonic antigen. It was labeled with both a near-infrared fluorescent dye (IRDye800CW) and radioactive Indium-111. Carcinoembryonic antigen is overexpressed in 95% of colorectal cancer cases. Using micro-SPECT and fluorescence imaging, from the first week of tumor growth, researchers visualized sub-millimeter pulmonary tumor colonies. Results also indicated dual-modality imaging can also guide tumor lesion resection which is critical for patients to achieve the best prognosis. An injection of Indium-111-DTPA-labetuzumab-IRDye800CW enables detection of tiny carcinoembryonic antigen. The same strategy, with a different tumor-targeting antibody, can also be used with other types of cancer, researchers said. Ultimately, study results demonstrate the possibility to detect micrometastases of colorectal cancer with fluorescence imaging and SPECT/CT before they're visible to the naked eye, and the broad application of the strategy could change oncology surgery and improve cancer patient prognoses.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.